subscribeSubscribe
Poxel to Report Its 2023 Annual Results by the End of April 2024

Poxel to Report Its 2023 Annual Results by the End of April 2024
BUSINESSWIRE
28 Mar 2024
Share Share
Poxel Announces PXL770 Granted Orphan Drug Designation from the U.S. FDA

Poxel Announces PXL770 Granted Orphan Drug Designation from the U.S. FDA
BUSINESSWIRE
03 Oct 2022
Share Share
Poxel Reports Financial Results for First Half 2022 & Provides Corporate Update

Poxel Reports Financial Results for First Half 2022 & Provides Corporate Update
BUSINESSWIRE
21 Sep 2022
Share Share
IMEGLIMIN with Novell Process IMEGLIMIN

IMEGLIMIN with Novell Process IMEGLIMIN
PRESS RELEASE
22 Aug 2022
Share Share
Poxel Announces Product Launch in Japan for TWYMEEG as Treatment for T2D

Poxel Announces Product Launch in Japan for TWYMEEG as Treatment for T2D
BIOSPACE
10 Sep 2021
Share Share
Vivek Ramaswamy’s Metavant hits a brick wall

Vivek Ramaswamy’s Metavant hits a brick wall
Nicole DeFeudis ENDPTS
20 Nov 2020
Share Share
Poxel posts phase 3 diabetes data ahead of approval decision

Poxel posts phase 3 diabetes data ahead of approval decision
N. P. Taylor FIERCE BIOTECH
24 Sep 2020
Share Share
Poxel Presents Imeglimin PhIII Results & PXL770 Preclinical Cardio-Renal Results

Poxel Presents Imeglimin PhIII Results & PXL770 Preclinical Cardio-Renal Results
BUSINESSWIRE
23 Sep 2020
Share Share
Poxel Reports Financial Results for First Half 2020

Poxel Reports Financial Results for First Half 2020
BUSINESSNEWS WIRE
15 Sep 2020
Share Share
Poxel, Sumitomo Pharma Announce +Ve Phase 3 Results from TIMES 2 Trial

Poxel, Sumitomo Pharma Announce +Ve Phase 3 Results from TIMES 2 Trial
BUSINESSWIRE
20 Dec 2019
Share Share